Market Assessment, Non Small Cell Lung Cancer [Afatinib Gilotrif Wave 2 ] LaunchTrends US 2014 Report

LaunchTrends: Gilotrif is a series of three post-launch syndicated reports designed to track physician perception and uptake of newly launched Gilotrif (Boehringer Ingelheim’s afatinib).
LaunchTrends: Gilotrif measures the impact of this novel agent on the metastatic non-small-cell lung cancer (NSCLC) market following launch. The study surveyed medical oncologists from the United States and conducted qualitative interviews with physicians. These reports evaluate physicians’ current awareness and perception of Gilotrif relative to other currently available therapies for metastatic NSCLC, current and anticipated usage of Gilotrif, as well as promotional activity of Gilotrif.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Non-Small-Cell Lung Cancer [Afatinib (Gilotrif) (Wave 2)] | LaunchTrends | US | 2014

Related Market Assessment Reports

Asthma | Unmet Need | Severe Asthma | US/EU | 2021

Asthma – Unmet Need – Detailed, Expanded Analysis – Severe Asthma (US/EU)

Pulmonary Hypertension – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Crohn’s Disease – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Pediatric Crohn’s Disease (US)

Atopic Dermatitis / Atopic Eczema – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (Adult) (US)